Welcome to the September 2018 edition of our Updates for the Advanced Practitioner in Oncology: Side Effect Management for Hematologic Malignancies newsletter. This month, we provide new links to the latest news and journal articles in this treatment space, featuring:
- The management of side effects before and after stem cell transplant, including a new warning about the use of azithromycin for bronchiolitis obliterans syndrome, the potential benefits of light therapy for depression, and the effect of nonmyeloablative/reduced-intensity conditioning on mucositis
- Recent data on the optimal amount of bedrest after intrathecal chemotherapy for hematologic cancers and how ruxolitinib dose-escalation may help decrease side effects for patients with myelofibrosis.
- Studies on the safety profiles of treatments for Waldenström macroglobulinemia and smoldering multiple myeloma
- Discussion of nephrotoxicity in CAR T-cell therapy and updated antifungal prophylaxis guidelines from the European Conference on Infections in Leukemia
If you haven’t yet, check out our new roundtable discussion, “Management of Adverse Events of Therapy in Hematologic Malignancies: A Case-Based Series and Overview.” Navigating through four case studies on thrombocytopenia, neutropenia and prophylaxis, three expert colleagues and I discuss important issues in managing side effects for hematologic malignancies and provide our own perspective and insight. We hope our discussion and all of our other resources empower you with practical strategies for managing the various adverse effects of therapy for hematologic malignancies.
Feel free to share this valuable resource with your colleagues. You can also contact me with comments or suggestions at any time through the JADPRO editors at firstname.lastname@example.org.
Allyson Price, MPAS, PA-C
Physician Assistant, Department of Leukemia
University of Texas MD Anderson Cancer Center